TEVA, US8816242098

Oppenheimer raises target for Teva stock to USD 52.00

Published on 10/12/2026 at 09:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oppenheimer set a USD 52.00 target on October 9, 2026. TD Cowen set USD 55.00 for Teva stock on October 1, 2026 with a Buy rating.

Key points in brief

Oppenheimer raised its Teva price target to USD 52.00 after FDA approval of WELTRUZA.
Teva's quarterly revenue was USD 4.14 billion, while analysts set targets as high as USD 55.00.
Teva last stood at USD 41.10 on October 9, 2026, with a market value of USD 47.9 billion.
Teva is scheduled to report third-quarter 2026 results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Oppenheimer raised its Teva Pharmaceutical Industries price target from USD 50.00 to USD 52.00 on October 9, 2026, while maintaining an Outperform rating, according to Investing.com. The revision followed U.S. approval of WELTRUZA, giving Teva stock a fresh commercial milestone while the latest reported quarter showed USD 4.14 billion in revenue.

Three dated catalysts shape the story

On October 1, 2026, TD Cowen began coverage with a Buy rating and a USD 55.00 target, according to MarketBeat. On October 2, Teva reported an interim 18-month analysis showing a 45.60 percent mean reduction in tic severity scores for ecopipam, as Teva reported. On October 9, Teva announced FDA approval of WELTRUZA, with three available strengths of 318 mg, 425 mg and 531 mg, according to Teva.

What does WELTRUZA add?

WELTRUZA is a once-monthly subcutaneous olanzapine injection for adults with schizophrenia. The FDA approval does not require loading doses, oral supplementation or post-injection monitoring, and Teva said the product will be available in the United States in the coming weeks.

The commercial opportunity comes with a defined launch hurdle. The approval materials describe weight gain and metabolic changes as known risks associated with olanzapine, so adoption will depend on physician choice, patient adherence and the product's safety profile. That balance helps explain why Oppenheimer expects a measured launch before meaningful revenue generation in the second half of 2027, according to Investing.com.

Revenue and valuation remain in view

Teva reported USD 4.14 billion of revenue in the second quarter of 2026, according to MarketBeat. The same report listed USD 0.02 in quarterly earnings per share, while the finance snapshot showed the stock last at USD 41.10 on October 9, 2026 at 4:00 p.m. ET in after-hours trading.

That USD 41.10 price was USD 0.92 below the USD 42.02 52-week high, a 2.19 percent gap calculated from the same market snapshot. Market capitalization stood at USD 47.9 billion on October 9, 2026, giving the approval and the target revisions a valuation context.

Next reporting date is November 3

Teva is scheduled to publish third-quarter 2026 results on November 3, 2026, according to Investing.com. That report will provide the next quantified test of whether innovative medicines can offset pressure in the generics business.

Stock context for the next report

Teva's NYSE and TASE listing, broad generic-drug base and growing specialty pipeline leave the market weighing near-term launch execution against longer-term product expansion. The further course of trading is shown by the continuously updated real-time quote of Teva stock.